Lataa...
Single Dose of Denosumab Effective for Management of Bisphosphonate-Refractory Hypercalcemia of Malignancy Related to Non-Small Cell Lung Cancer
Background: First line therapy for hypercalcemia of malignancy (HCM) includes cancer directed treatment and bisphosphonate therapy. Denosumab is effective in bisphosphonate-refractory HCM (BR-HCM), approved for treatment with dosing schedule at 1, 8, 15, and 29 days and then monthly. Clinical Case:...
Tallennettuna:
| Julkaisussa: | J Endocr Soc |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8089289/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.453 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|